• Oncology genomic tests were covered by 87.7% of plans (compared with 90.2% last year) • Cancer/oncology was consistently reported the top concern from medical and budgetary points of view… Click to show full abstract
• Oncology genomic tests were covered by 87.7% of plans (compared with 90.2% last year) • Cancer/oncology was consistently reported the top concern from medical and budgetary points of view (Figure 6) • Compared with last year’s survey, the percent citing cancer/oncology as a top concern from a: o Medical point of view in 2016 decreased from 50%, in 5 years (2021) increased by 7.5% from 42.5% o Budgetary point of view in 2016 increased 14.3% (from 35.7%) and in 5 years (2021) increased by 3.4%
               
Click one of the above tabs to view related content.